Compass Therapeutics (NASDAQ:CMPX) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a research note published on Monday,Benzinga reports. They currently have a $24.00 price objective on the stock. Several other equities research analysts have also recently commented on the company. Jefferies Financial Group boosted their target price on Compass Therapeutics […]